{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T04:03:01Z","timestamp":1785211381416,"version":"3.55.0"},"reference-count":72,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Emerging Drugs"],"published-print":{"date-parts":[[2024,7,2]]},"DOI":"10.1080\/14728214.2024.2346590","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T12:13:57Z","timestamp":1714133637000},"page":"251-261","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":17,"title":["Emerging and traditional 5-\u03b1 reductase inhibitors and androgen receptor antagonists for male androgenetic alopecia"],"prefix":"10.1080","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8664-7723","authenticated-orcid":false,"given":"Aditya K.","family":"Gupta","sequence":"first","affiliation":[{"name":"Mediprobe Research Inc","place":["London, Canada"]},{"name":"University of Toronto","place":["Toronto, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mesbah","family":"Talukder","sequence":"additional","affiliation":[{"name":"Mediprobe Research Inc","place":["London, Canada"]},{"name":"BRAC University","place":["Dhaka, Bangladesh"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Williams","sequence":"additional","affiliation":[{"name":"Farjo Hair Institute","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,4,26]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15323"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.913116"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2009-1474"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.15427"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1959506"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.14895"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17738"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03780.x"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(98)70007-6"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70081-2"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70296-3"},{"key":"e_1_3_4_14_1","unstructured":"EMA. List of nationally authorised medicinal products (active substance: finasteride); procedure no.: PSUSA\/00001392\/202108; reference no. Ema\/208932\/2022 2022 [cited 2024 17 Mar]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/psusa\/psusa-00001392-202108"},{"key":"e_1_3_4_15_1","unstructured":"Study used to push non-fda-approved topical finasteride knocked by top German rx journal (post-finasteride syndrome foundation) 2023 [cited 2024 17 Mar]. Available from: https:\/\/www.pfsfoundation.org\/news\/study-used-to-push-non-fda-approved-topical-finasteride-knocked-by-top-german-rx-journal\/"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP202119"},{"key":"e_1_3_4_17_1","unstructured":"US FDA. PROPECIA\u00ae (finasteride) tablets for oral use 2022 [cited 2024 18 Mar]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/020788s030lbl.pdf"},{"key":"e_1_3_4_18_1","unstructured":"US FDA. PROSCAR\u00ae (finasteride) tablets for oral use 2021 [cited 2024 19 Mar]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/020180s047lbl.pdf"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155342"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.05.007"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2109567"},{"key":"e_1_3_4_22_1","unstructured":"Mother to baby | fact sheets [Internet]. Brentwood (TN): Organization of Teratology Information Specialists (OTIS); 1994-. Finasteride 2022 [cited 2024 20 Mar]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK582707\/"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.2164\/jandrol.109.009381"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-2203"},{"key":"e_1_3_4_25_1","unstructured":"Mirabello S What happens when you stop taking finasteride? 2023 [cited 2023 4 Oct]. Available from: https:\/\/nowpatient.com\/blog\/what-happens-when-you-stop-taking-finasteride"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.5021\/ad.22.027"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.09.018"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.10.049"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.188652"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13182"},{"key":"e_1_3_4_31_1","unstructured":"Dutasteride Pregnancy and Breastfeeding Warnings. 2022. [cited 2023 4 October]. Available from: https:\/\/www.drugs.com\/pregnancy\/dutasteride.html"},{"key":"e_1_3_4_32_1","unstructured":"US FDA. AVODART (dutasteride) soft gelatin capsules: highlights of prescribing information. 2020 [cited 2023 3 Oct]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/021319s032lbl.pdf"},{"key":"e_1_3_4_33_1","unstructured":"AVODART (Dutasteride) 0.5 mg soft capsules; package leaflet: information for the patient 2023 [cited 2024 16 Jan]. Available from: https:\/\/www.medicines.org.uk\/emc\/files\/pil.6758.pdf"},{"key":"e_1_3_4_34_1","first-page":"137","article-title":"Mesotherapy using dutasteride-containing solution in male pattern hair loss: a controlled pilot study","volume":"20","author":"Abdallah M","year":"2009","unstructured":"Abdallah M, El-Zawahry K, Besar H. Mesotherapy using dutasteride-containing solution in male pattern hair loss: a controlled pilot study. J Pan Arab Leag Dermatol. 2009;20:137\u2013145.","journal-title":"J Pan Arab Leag Dermatol"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1159\/000510697"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04535.x"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.7241\/ourd.20131.08"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18066"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.04.132"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2019.04.006"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1590\/s1677-5538.ibju.2017.0531"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2017.29.4.525"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-018-4996-3"},{"key":"e_1_3_4_44_1","unstructured":"UK MHRA. The risk of male breast cancer with finasteride (public assessment report) 2009 [cited 2024 22 Jan]. Available from: https:\/\/assets.publishing.service.gov.uk\/media\/5df7610c40f0b60959adc737\/Finasteride_risk_of_male_breast_cancer.pdf"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.07.048"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S398950"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14678"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/jvc2.53"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.10.048"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.04.054"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.034"},{"key":"e_1_3_4_52_1","unstructured":"Ghosh S Alopecia treatment market outlook (2022 to 2032): future market insights; 2022 [cited 2023 28 Dec]. Available from: https:\/\/www.futuremarketinsights.com\/reports\/alopecia-treatment-market"},{"key":"e_1_3_4_53_1","unstructured":"Hair loss treatment products market size & share analysis - growth trends & forecasts (2023 \u2013 2028) mordor intelligence; 2023 [cited 2023 28 Dec]. Available from: https:\/\/www.mordorintelligence.com\/industry-reports\/hair-loss-treatment-products-market"},{"key":"e_1_3_4_54_1","unstructured":"PubChem compound summary of alfataradiol 2023 [cited 2023 27 Dec]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Alfatradiol"},{"key":"e_1_3_4_55_1","unstructured":"Episteride structure 2023 [cited 2023 27 Dec]. Available from: https:\/\/commons.wikimedia.org\/wiki\/File:Epristeride.svg"},{"key":"e_1_3_4_56_1","unstructured":"PubChem compound summary of clascoterone 2023 [cited 2023 27 Dec]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/substance\/483925126"},{"key":"e_1_3_4_57_1","unstructured":"PubChem compound summary of pyrilutamide 2023 [cited 2023 28 Dec]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/50940514#section=2D-Structure"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0379.2011.07802.x"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2007.06295.x"},{"key":"e_1_3_4_60_1","first-page":"59","volume-title":"Current pharmaceutical design","author":"Frye SV","year":"1996","unstructured":"Frye SV. Inhibitors of 5-alpha reductase. In: Sliskovic DR, editor. Current pharmaceutical design. Vol. 2. The Netherlands: Netherlands Benthan Science Publishers BV; 1996. p. 59\u201384."},{"key":"e_1_3_4_61_1","unstructured":"A phase 2 study to evaluate the safety and efficacy of cb-03-01 Solution a Comparator Solution and Vehicle Solution in Males with Androgenetic Alopecia (NCT02279823): ClinicalTrials.gov; 2016 [cited 2023 10 Oct]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02279823"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.5402\/2011\/241953"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1159\/000017954"},{"key":"e_1_3_4_64_1","unstructured":"Fultinavi\u010di\u016bt\u0117 U Kintor succeeds in Phase II study of US males with androgenetic alopecia 2023 [cited 2023 2 Oct]. Available from: https:\/\/www.clinicaltrialsarena.com\/news\/kintor-androgenetic-alopecia-kx-826\/"},{"key":"e_1_3_4_65_1","unstructured":"Kintor Pharma announces first patient dosing of phase III clinical trial of KX-826 (Pyrilutamide) for treating androgenic alopecia patients in China 2022 [cited 2023 2 Oct]. Available from: https:\/\/www.prnewswire.com\/news-releases\/kintor-pharma-announces-first-patient-dosing-of-phase-iii-clinical-trial-of-kx-826-pyrilutamide-for-treating-androgenic-alopecia-patients-in-china-301452532.html"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/smtd.202201293"},{"key":"e_1_3_4_67_1","unstructured":"Lama SC Chang MW. Kintor advances with GT20029 clinical trials for hair loss 2023 [cited 2024 20 Mar]. Available from: https:\/\/hairscience.org\/news\/gt20029-topical-androgen-degrader\/"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12352"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1177\/039463201202500435"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1089\/107555302317371433"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/549721"},{"key":"e_1_3_4_72_1","first-page":"441","volume-title":"Pygeum Africanum (Prunus Africana). Androgenetic alopecia from A to Z","author":"Anastassakis K","year":"2022","unstructured":"Anastassakis K. Pygeum Africanum (Prunus Africana). Androgenetic alopecia from A to Z. Vol. 2. Drugs, Herbs, Nutrition and Supplements: Springer; 2022. p. 441\u2013444."},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.5538\/1887-5181.2016.25.5"},{"key":"e_1_3_4_74_1","unstructured":"Package leaflet of CARETOPIC (finasteride) 2.275 mg\/ml cutaneous spray solution 2023 [cited 2024 17 Mar]. Available from: https:\/\/www.codifa.it\/foglietti-illustrativi\/Caretopic"}],"container-title":["Expert Opinion on Emerging Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14728214.2024.2346590","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T05:42:44Z","timestamp":1738561364000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728214.2024.2346590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,26]]},"references-count":72,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7,2]]}},"alternative-id":["10.1080\/14728214.2024.2346590"],"URL":"https:\/\/doi.org\/10.1080\/14728214.2024.2346590","relation":{},"ISSN":["1472-8214","1744-7623"],"issn-type":[{"value":"1472-8214","type":"print"},{"value":"1744-7623","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-01-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}